The US Food and Drug Administration (FDA) approved Roche’s Xofluza for the treatment of acute uncomplicated influenza in children aged five years and above who have been symptomatic for not more than 48 hours. This approval marks the first oral influenza medicine approved in the United States for children in the particular age group. Levi […]
Continue Reading
Roche Announced that, the Food and Drug Administration (FDA) of the United States has issued emergency use authorization (EUA) for the cobas SARS-CoV-2 Duo for use on the fully automated cobas 6800/8800 Systems, along with expanding the covid-19 portfolio of Roche. This has been first automated and real-time RT-PCR assay for the in vitro qualitative […]
Continue Reading
The Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom has now granted approval for faricimab developed by Roche for the individuals with the wet age-related macular degeneration (wet AMD) and the impairment in vision because of the diabetic macular oedema (DMO). An eye injection known as faricimab has been bispecific antibody that […]
Continue Reading
The Food and Drug Administration (FDA) of the United States has now granted the emergency use authorization to a new at-home corona virus tests amid the shortages of the testing kits and increasing rates of the corona virus cases in the United States. In the previous month, the US FDA has also announced that, the […]
Continue Reading
Roche and Ibex Medical Analytics, a world leader in the artificial intelligence-based cancer diagnostics company has partnered for the purpose of jointly developing an embedded image analysis workflow for the pathologists for the purpose of seamlessly accessing the artificial intelligence algorithms, along with the insights and decision supporting tools by using the NAVIFY Digital Pathology, […]
Continue Reading
On 28th June 2021, the company Roche announced, the European Commission has given the approval for ENSPRYNG for the purpose of treating the adolescents and the adults over 12 years of age, who are living with the anti-aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD). The treatment is going to be a monotherapy, or […]
Continue Reading